Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages
Abstract Squamous cell carcinomas are the most common head and neck malignancies. Significant progress has been made in standard therapeutic methods combining surgery, radiation, and chemotherapy. Nevertheless, the 5-year survival rate remains at 40–50%. Immune checkpoint inhibitors (ICIs) are a new...
Main Authors: | Hui Dong, Mengli Li, Chen Yang, Wei Wei, Xianglei He, Gang Cheng, Shibing Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-01-01
|
Series: | Cancer Cell International |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12935-022-02846-x |
Similar Items
-
Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma
by: Darrin V. Bann, et al.
Published: (2016-09-01) -
Clinical Advances and Future Directions of Oncolytic Virotherapy for Head and Neck Cancer
by: Zhan Wang, et al.
Published: (2023-11-01) -
Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma
by: Florencia Veigas, et al.
Published: (2021-03-01) -
Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
by: Shinsuke Suzuki, et al.
Published: (2021-10-01) -
Tumor Microenvironment in Head and Neck Squamous Cell Carcinomas
by: Görkem Eskiizmir
Published: (2015-09-01)